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Despite improvements in the diagnosis and treatment of breast cancer 
(BC), approximately 30% of women diagnosed in the early stages develop 
metastatic disease. It is therefore extremely important to determine new 
biomarkers that can monitor the effectiveness of the therapy, that can 
allow the early detection of micro-metastases, that enable to predict the 
response to the treatment and to evaluate intra-tumor heterogeneity. As 
part of the search for diagnostic, prognostic and possibly therapeutic 
biomarkers, a very promising field is the analysis of circulating biomarkers 
(CBM) released from the primary tumor or from the sites of metastases 
through liquid biopsy, a minimally invasive and repeatable method that has 
been considered as an approach of diagnostic utility to complement 
traditional biopsy techniques. In particular, the evaluation and analysis of 
the mutational profiles of circulating tumor cells (CTCs) and circulating 
tumor DNA (ctDNA) in the blood have shown that they can provide useful 
information in the care of patients with BC. 
For this purpose, this three-year PhD project has been mainly focused on 
the recovery and the characterization of CTCs obtained from BC patient 
samples by liquid biopsy. The experimental work was mainly performed in 
the clinical trial CITUCEL, "CIrculating TUmor CELls (CTCs) and circulating 
tumor DNA (ctDNA) in breast cancer patients: a prospective study", a 
spontaneous translational protocol conducted at the Ospedale Policlinico 
San Martino (HSM) in Genoa. It is a single-centre translational, 
observational, interventional, non-pharmacological study which therefore 
does not provide any type of additional treatment or exclusion from the 
therapeutic gold standard, more than clinician choice as for clinical 
practice. 
In addition, part of the experimental activity was conducted within the 
study “Genetic Barcoding to evaluate the Reliability of Liquid Biopsies in 
featuring Triple Negative BC (TNBC) and Hormone negative (HR) /HER2 
over-expressed BC heterogeneity- BaReLiB”, supported by AIRC Investigator 
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Grant 2017, in which TNBC and HR-/HER2+ BC heterogeneity is evaluated 
using liquid biopsy and genetic barcoding in mouse model. 
Finally, additional in vitro preliminary experiments have been conducted 
with the purpose to evaluate the effect of the treatment with Ixazomib, 























Breast Cancer (BC) it is the leading cause of cancer death in women and 
has the highest incidence rate1; most of the time, the disease requires a 
multidisciplinary approach, or a combination of therapies. Treatment plans 
often involve a primary therapy, generally surgery or radiation therapy, in 
addition to an adjuvant and/or neoadjuvant therapy.  
In particular, neoadjuvant therapies are delivered before the main 
treatment, to help reduce the size of a tumor or kill cancer cells that have 
spread; adjuvant therapies are delivered after the primary treatment, to 
destroy remaining cancer cells. In general, different biological subtypes of 
BC display differences in propensity to metastatic spread. Biological 
subtypes are classified according to the expression of steroid hormone 
receptors (estrogen (ER) and progesterone (PgR)) and HER2 (human 
epidermal growth factor receptor 2).  
In luminal cancers metastasis is not frequent, but this group is 
heterogeneous, comprising luminal A and B, with different aggressiveness 
and treatment options. There is a peak of relapses at about 2-3 years after 
the surgery, but the rate of metastasis remains relatively high after the 
peak, because disseminated cells may stay dormant even for as long as 20 
years and start to proliferate upon some triggering event.  
In tumors HER2 positive (about 20% of cases) prognosis is relatively worse 
than in luminal BC, although they can be treated with targeted anti-HER2 
therapy. Triple negative BC (TNBC), that lack the expression of ER, PR, 
HER2, which constitutes about 15% of all cases, is heterogeneous itself, 
comprising different subtypes, including basal like, immune-modulatory, 
luminal androgen receptor, mesenchymal and claudin low; it is highly 
aggressive and low survival rates. TNBC tend to disseminate quickly (also 
with a peak in the first 2-3 years after surgery) and the percentage of 
metastases is high.  
However, in contrast to luminal cancers, the rate of distant metastases in 
TNBC becomes significantly lower after five years, thus dormancy of 
disseminated is less common in this subtype2. 
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These intrinsic differences in BC subtypes raise several opened questions, 
such as what the routes to metastasis in BC are, what can be learned about 
them by analyzing CTCs and how the knowledge gained by CTC analysis 
may impact therapeutic decisions. There are two main hypotheses 
describing cancer dissemination: linear progression, according to which, 
metastatic potential is gained gradually and the whole process proceeds in 
steps and needs time, and parallel progression, according to which 
dissemination takes place early on even before clinical manifestation of the 
tumor. In the linear progression model, the evolving primary tumor gives 
rise to metastases due to increasingly aggressive and invasive phenotypes 
of the subclones of tumor cells. This model is in agreement with the 
postulated role of the epithelial-to-mesenchymal transition (EMT) in cancer 
and assumes active degradation of the stroma and migration into blood 
vessels by the motile, invasive single cells that broke loose from the 
epithelial monolayer3. 
In contrast to that, parallel progression postulates intravasation by passive 
shedding, which may take place shortly after the angiogenic switch, 
occurring during the early, pre-invasive stage of tumor development. 
Although the concept of linear progression is well established, recently 
many reports support parallel progression hypothesis. Accepting the 
parallel progression model, even if only for some subtypes or specific cases 
of BC, calls for a close control of the current diagnostic and therapeutic 
procedures and has implications for the CTCs research. Early dissemination, 
occurring before the appearance of any symptoms, precludes prevention, 
unless precautionary screening of the healthy population is considered, but 
even in this case, the probability of detecting CTCs in time is negligible3. 
Even if CTCs data could not be used for the prevention of metastasis, they 






1.1      Liquid Biopsy 
In 2020 a total of 54.976 new cases (equal to 14.6% of all new diagnoses) 
of BC were diagnosed in Italy4. With the exception of cutaneous 
carcinomas, BC is also the most common cancer in women in Italy, where 
about one malignant tumor every three (30%) is a BC. Therefore, there is 
an urgent need to find novel biomarkers able to improve the therapeutic 
management of BC patients. 
Recently, the detection of Circulating Tumor Cells (CTCs), circulating Tumor 
DNA (ctDNA), Exosome (Ex) and other Circulating Bio-Materials (CBM) in 
the blood has demonstrated to provide useful information for the clinical 
management of BC patients: their characterization could identify potential 
predictive and prognostic biomarkers, through a simple blood test defined 
as liquid biopsy. The liquid biopsy has emerged in the last ten years as an 
appealing non-invasive strategy to support early cancer diagnosis and 
follow-up interventions. It represents a diagnostic technique able to trace a 
tumor molecular profile, both at diagnosis and during the treatment and 
during the follow up, capturing the changing shape of the tumor. From a 
single sample it is possible to isolate different circulating macromolecules 
such as CTCs, Ex, platelets and circulating DNA/RNA, in various body fluids 
among which the most suitable is represented by the blood, but it is 
possible to isolate these components also in pleural fluid, urine and 
cerebrospinal fluid.  The biological liquid that is mainly used is plasma, 
because it is easy to obtain and for this reason is the most widely used. 
Compared to common diagnostic tools liquid biopsies represent a great 
improvement, allowing multiple sampling from the same patient at 
different times, therefore providing the dynamic monitoring of tumor 
changes not achievable with a single sample and giving insight about the 
whole tumor (including possible metastasis). Infact, the molecular genetics 
profile of a tumor changes over time and standard tissue biopsies are not 
able to represent the overall view of the tumor5. Traditionally, routine 
histological evaluation and immunohistochemical study have an essential 
role in several aspects of diagnosis in both neoplastic and non-neoplastic 
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disorders. However, tissue biopsy is an invasive procedure and so is often 
not easily repeatable, also considering the cost and the risk factors.  
It is now clear the chance to get benefits of molecular information about 
primary tumors by using liquid biopsies and compared the result of liquid 
biopsy with tumor biopsy. There are still controversies in regards of the 
fact that liquid biopsy can take the place of tissue biopsy or will support 
“gold standard” tissue biopsies. Its minimally invasive nature could in 
principle provide a new insight for malignancy checking without delay, 
expenses, and risks, possibly at a microscopic stage and before the 
radiological tests. From the perspective of bio-detection, any biomarkers 
that are highly associated with tumor growth and metastasis, can be 
indicators of carcinomas: CTCs, ctDNA, and Ex have broad biomarker 
potential because they can timely and dynamically represent the tumor’s 
genetic status both for diagnosis and for prognosis applications. Therefore, 
liquid biopsy could have a better sensitivity and may be more convenient 
as a cancer diagnosis tool in comparison with the traditional tissue biopsy 
method.  
Although imaging and tissue biopsy are still the standard approach in solid 
tumor screening and monitoring, it is possible that CTCs detection with 
imaging combination could be the greatest choice. Infact, the quick 
diagnostic value of CTCs in primary stages of cancer has been considered 
several times and, in animal models, it was shown that CTCs were 
established in the very early stage implying the fact that the tumor cells 
had spread prior to diagnosis. The exceeding indication showed that the 
CTCs may be a valuable tool for very early cancer diagnosis. Moreover, 
many researchers have indicated a positive connection of ctDNA quantity 
and tumor stage to predict the severity of malignancies and efficacy of 
treatment6. 
 The use of Ex as a predictive biomarker and indicator of treatment 
response completely relies on its protein and miRNA content. Thanks to 
the latest advances in molecular technology detection, such as Next 
Generation Sequencing (NGS), whole-genome shotgun bisulfate 
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sequencing, and tagged-amplicon deep sequencing, the importance of 
liquid biopsy has constantly increasing. Most scientists believe that its use 
in cancer treatment will support the conventional tissue biopsy method 
instead of replacing it. Furthermore, using a blood test along with tissue 
will be a breakthrough because, more often than not, the traditional biopsy 
does not pick enough tissue7. 
Unfortunately, discordant detection results are frequently encountered 
when those single biomarkers are analyzed; this inconsistency probably 
stems from tumor heterogeneity as well as varied analytical 
methodologies.  
Several recent publications have revealed that the joint detection of 
different biomarkers or the use of multiple methods with different 
principles can significantly improve the sensitivity with which cancers can 
be differentiated at early stages8. A potential solution could be 
represented by the “integrated liquid biopsy”, defined as integrating 
multiple liquid biopsy biomarkers or detection methods for improved 
analytical sensitivity and specificity to refine cancer management. Since a 
single biomarker is inefficient in accurately identifying most cancers, 
integrated liquid biopsy using multiple markers might be a promising 
method to facilitate early detection and treatment of cancer. For example, 
the tendency of ctDNA to degrade rapidly makes its accurate detection 
particularly challenging: Ex-ctDNA integration may elicit compensated 
information because resistant cell-originated Ex reveals alterations in the 
cancer microenvironment, and sensitive cell-originated ctDNA may indicate 
mutation evolution.  
Infact, tumorigenesis, metastasis and tumor evolution are the typical forms 
of cancer development, and the above-noted biomarkers can reflect the 
accumulation of either genetic mutations or epigenetic modifications. 
During early tumorigenesis, ctDNA can be used to assess diseases from just 
a few million malignant cells before radioscopy. Additionally, both Ex and 
ctDNA can be released from all composites of cancer niches to trigger 
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tumor growth and metastasis, suggesting their potential in very early-stage 
detection and predicting tumor growth and metastasis9.  
To note combination analysis of ctDNA and CTCs has alreadyshown to 
allow a more reliable classification of patients in risk categories 6b.  
Overall, until today, liquid biopsy represents the potential best strategy to 
overcome the hurdle of tumor heterogeneity and to find out new 
predictive biomarkers, important for the choice of more personalized 
treatment strategies. 
 
1.2       CTCs 
CTCs are cells that originate from the primitive tumor and that, 
accumulating genetic and epigenetic mutations, have acquired the ability 
to migrate into the bloodstream. CTCs are usually a rare finding, not 
present in all patients, but once identified their presence indicates a 
negative prognosis. The existence of CTCs in the blood of metastatic 
prostate cancer patients was reported for the first time by Thomas 
Ashworth, an Australian physician, in 1869.  
In recent studies, the detection of CTCs and ctDNA in the blood have 
demonstrated to provide useful information for the clinical management of 
BC. In particular, the count of CTCs has been included among the factors of 
bad prognosis for the patients with primitive and metastatic mammary 
tumor in the 8th edition of the American Joint Committee on Cancer (AJCC) 
cancer staging manual10. Until now, metastasis is the most challenging 
process of tumor and the key cause of cancer-associated death (9 of 10 
deaths).  
The “seed and soil” hypothesis described that tumor invasion - the intrinsic 
characteristics of the tumor cells (seeds) and host microenvironment (soil) 
- are the central elements of the place of tumor development. Watanabe in 
1954 by injecting bronchogenic carcinoma cells of mice showed that the 
CTCs can be the key role players in metastasis. In addition, it was shown 
that the metastases development, to some extent, depends on the size and 
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quantity of the CTC clusters. The CTCs are highly heterogenic, and several 
types of CTCs are suggested, which are given below:  
 
Traditional CTCs: the hallmark of these cells is having large and irregular 
shapes, with an intact, viable nucleus; they express cytokeratins with 
epithelial origin and nonhematopoietic origin (they do not have CD45). 
 
Cytokeratin-negative (CK−) CTCs: cancer stem cells passing through the 
epithelial-mesenchymal transition steps and forming the cytokeratin-
negative CTCs. They can be opposed to treatment and are the most 
potential CTCs subpopulation to invade and form metastasis because they 
do not have cytokeratins and CD45.  
 
Apoptotic CTCs: the traditional CTCs that undergo apoptosis. They are 
distinguishable with nuclear fragmentation or cytoplasmic blabbing 
associated with cell death. The proportion of apoptotic CTCs compared 
with the traditional CTCs can be a predictor of treatment efficacy. 
 
Small CTCs: recognized as the cytokeratin-positive and CD45-negative cells, 
similar in size to leukocytes. Notably, the small CTCs have been concerned 
with progressive disease and differentiation into small cell carcinomas, 
which often need special therapeutic strategies. 
 
However, the new classification system suggested that CTCs should be 
characterized by their size and the expression of several markers such as 
EpCAM. The principles of CTCs isolation, quantification, and 
characterization is based on the different physical characteristics 
(magnitude, electric charges) and genetic properties of the CTCs compared 
with the non-tumor cells11. 
CTCs may undergo to epithelial-mesenchymal transition (EMT) during 
dissemination. Although normal epithelial cells are immobile, some 
cancerous epithelial cells may begin expressing proteins associated with 
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motility and increase expressing proteins involved in forming connections 
between cells during embryonic development. This transformation 
produces mobile “mesenchymal” cells that can migrate and form other 
lesions. Cancer cells that have an EMT phenotype can penetrate and pass-
through blood vessel walls and enter the bloodstream. These CTCs 
eventually attach to endothelial cells of blood vessels and exit the 
bloodstream, forming new metastatic lesions in other organs. 
However, which CTCs subtype exhibits the highest metastasis-initiating 
activity remains unclear, but epithelial-type CTCs have a higher potential to 
translate protein and proliferate. Moreover, epithelial-type CTCs had the 
most metastatic potential and the proportion of epithelial-type CTCs 
shown associations with distant metastases and prognosis. Hence, 
immunoaffinity-based enrichment technologies relying on epithelial cell 
surface markers can underestimate the number of CTCs but may quantify 
metastatic potential cells. EMT and the acquisition of stem cell properties 
are related (i.e., induction of EMT leads to the expression of stem cell 
markers, increased self-renewal, and increased tumor-initiating potential).  
It is thus important to elucidate the biological characteristics of CTCs 12.  
A recent study reported the use of CD44, CD133, and vimentin as 
expression markers. Moreover, the distribution of these markers in CTCs 
may be changing during disease progression and treatment.  
Not surprisingly, CTCs found in the blood of patients with different BC 
subtypes have diverse phenotypes. For patients with luminal cancers CTCs 
were predominantly epithelial, while for other subtypes predominantly 
mesenchymal. Interestingly, the presence of mesenchymal CTCs was 
described a predictive factor, regardless of BC subtype. It seems that the 
hybrid phenotype may be the most predictive. Co-expression of E and M 
markers in CTCs is associated with cancer progression and metastasis13. 
Although the CTCs population is extremely small when compared to other 
cell populations in the blood, thus limiting our understanding of their 
biology and clinical utility, unlike the case of tissue biopsy repeating 
sampling to obtain more cells is possible. This makes CTCs an ideal and 
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clinically practical material for investigations of not only basic biological 
and clinical characteristics of cancer cells but of tumor heterogeneity and 
drug resistance as well. Due to recent technological advances, proteomic 
and genomic techniques that require only a small amount of sample are 
now available. The sheer number of CTCs circulating in the blood of a 
patient is the simplest and statistically significant factor in assessing the 
outcome. In BC, CTCs are detected in about 20-30% of early and around 
60% of advanced patients. Interestingly, BC subtypes seems not have an 
impact on absolute CTCs numbers as well as CTCs positivity rates, except 
for the very high CTCs counts observed more frequently in luminal A and 
TNBC and the lower prognostic impact for the HER2+ disease. Therefore, 
more information to compare and assess CTCs numbers reliably are 
necessary14. 
Furthermore, CTCs numbers can vary in the blood of the same patient and 
is important to determine factors influencing this fluctuation: simple 
methodology factors like blood drawing (arterial vs. venous, the time of 
day, the technique) or clinical factors, including overall patients’ status and 
clinical features, but also the important issue of CTCs mobilization by 
therapeutic intervention, like radiotherapy, surgery or even biopsy, could 
affect CTCs recovery.  
Given the fact that the standard cut-off is considered to be ≥1 in the (neo) 
adjuvant setting and ≥5 in the metastatic setting, the enumeration of CTCs 
represents an effective prognostic and predictive biomarker; it can be 
explained by the metastatic potential of these cells, but almost certainly it 
is not always the case15. Alternatively, CTC shedding may be associated 
with the increased aggressiveness of the tumor. Clarification of the factors 
determining the CTCs release pattern is thus an important goal that can be 
achieved only by systematic longitudinal studies of CTCs numbers in a large 
patients’ cohorts. 
Besides enumeration, new techniques, which enable to efficiently isolate 
CTCs from patients’ blood provide the possibility of a detailed molecular 
analysis. Genotype analysis of CTCs in BC is tuned to detect the most 
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common driver mutations and to assess the difference between CTCs and 
primary tumor. Frequently mutated genes in BC CTCs include TP53 (mostly 
in TNBC), PIK3CA, ERBB2, KRAS and ESR1. Moreover, mutations in these 
genes display high degree of intra-patient heterogeneity. Thus, it is 
important to recognize mutations at the single-cell level, since they may 
give rise to metastatic clones, while remaining undetectable in the greater 
part of analysis. Interestingly, the analysis of the receptor status in CTCs 
from metastatic patients demonstrated that most of CTCs were estrogen 
and progesterone receptor negative, while primary tumors were receptor 
positive. This could reflect a mechanism of escape from endocrine therapy. 
In contrast to that, in receptor-negative BC changes in receptor status 
between primary tumor and CTCs are usually minimal. Discordance in 
expression between primary tumor, CTC and metastases was also observed 
for HER216. 
It is also worth considering that, when a tumor cell enters the circulation 
and becomes CTC, these cells are exposed to various stresses associated 
with this new microenvironment and them reversible re-program themself 
to cope with new challenge.  Alternatively, some protection from these 
factors can be achieved by cells’ clustering, but the origin of CTCs clusters is 
subject of debate. Originally, it was surmised that CTCs clusters arise by 
collective invasion and dissemination of oligoclonal groupings of tumor 
cells, but recent findings revealed that they can be formed by tumor cells 
aggregation within vasculature. This aggregation is induced by homophilic 
interactions of CD44 molecule, the receptor for hyaluronic acid. It was 
demonstrated in mouse models that BC metastases are of polyclonal 
origin, which is inconsistent with the dissemination and expansion of a 
single cell but can be easily explained by the dissemination of CTCs 
clusters17.  
However, CTCs clusters are rare (about 10 times more rare than single 
CTCs), but have up to 50 times more metastatic potential than single CTCs. 
Molecular profiling of single and clustered CTCs revealed high expression of 
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desmosomal junction protein plakoglobin in clusters, which may be due to 
its function in maintaining strong cell-cell contacts. 
Anyway, CTCs analyses give important information with diagnostic and 
therapeutic relevance and since they represent tumor cells’ population 
currently present in the circulation and, as such, can serve as a source of 
invaluable information, considering tumor properties, more accurate, 
recent and relevant than tissue analysis from the primary tumor obtained 
during surgery or biopsy. Learning from that input, it is possible to modify 
the treatment and either hold the potential metastases in check, by 
knowing their biology, or, in more advanced cases, tailor the treatment 
according to the specific properties and sensitivities of the circulating cells. 
This can be especially important in case of ER+ BC, which tends to lose 
responsiveness to the usual treatments. CTCs longitudinal screening may 
detect this change and flag the necessity for therapy modification. Gaining 
more knowledge on the issue if some routes of metastasis are more likely 
in specific subtypes of BC would be invaluable for the CTCs data 
interpretation. In early BC (EBC) the accumulated data about the biology of 
CTCs released by the primary tumor are scarce. Tumor cell dissemination 
has been suggested to occur early in BC progression, even before the 
tumor has become invasive. A single study on 73 patients with either 
ductal or lobular carcinoma in situ reported that three patients (4.1%) had 
1 CTC per 22.5mL of blood. Prognostic significance of CTCs was also clearly 
demonstrated in adjuvant setting: analysis of 206 patients enrolled in the 
same study with known CTC status at 5 years, revealed that CTCs-positivity 
was found in 7.8% and was associated with a 6-fold increase in recurrence. 
Prognostic value of CTCs has been demonstrated in metastatic BC by many 
studies. CTCs were detectable in approximately 60% of MBC patients, and a 
CTC count ≥5 cells per 7.5mL of blood was associated with significantly 
worse progression-free survival (PFS) and overall survival (OS, providing 
evidence for its clinical validity18.  
However, the question if either CTCs number or/and CTCs phenotype may 
serve as a criterion for therapy decisions in still unsolved. There are 
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currently insufficient data to support the use of CTCs status as a criterion 
for therapeutic choice and it still remains to be investigated in prospective 
trials that show how it can be used for a prediction of therapy response 
and an improved clinical outcome. 
 
1.3      ctDNA 
Circulating tumor DNA (ctDNA) merely refers to fragmented DNA, 
originates from tumor cells itself. It represents a part of cfDNA /cell free 
DNA, and has a substantial fluctuant proportion ranging from <0.1% to 
>90% in cfDNA; in general, cfDNA levels in the blood are elevated in 
patients with carcinoma compared to healthy individuals. With lots of 
ctDNA released into the circulatory system by tumor cell apoptosis or 
necrosis, the quantity of ctDNA could reflect tumor burden in cancer 
patients. How to detect and analyze ctDNA from the background of normal 
cfDNA is a big challenge in the development of liquid biopsy application 
because it is highly fragmented to on average 170bp in length. Moreover, 
ctDNA may occasionally be present only as a minimal fraction in the 
circulation compared with the wild-type cell-free DNA (cfDNA) released 
from normal cells. In healthy individuals, cfDNA originates from 
hematopoietic cells while in cancer patients is tissue-specific, as the 
majority of their ctDNA comes from the tumor tissue of origin. The ratio of 
ctDNA to cfDNA depends on tumor and immunological factors, tumor 
burden and progression, and blood clearance mechanisms. If found, ctDNA 
has the potential to capture complete information on genetic alterations, 
including the somatic single-nucleotide variations present in the tumor and 
its metastases, and also to longitudinally monitor these mutations 
throughout the course of patient treatment. In addition, ctDNA is 
considered to be released from apoptotic and necrotic tumor cells, and its 
blood circulation half-life ranges from minutes to several hours, which 
makes it a dynamic, almost real-time, biomarker for cancer monitoring19. 
Targeted NGS, which generates sufficiently high coverage over a certain 
region, is therefore required, and ctDNA molecular analysis and 
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identification of these low-frequency variants is important for detection of 
cancer in its early stages and appropriate diagnosis20.  
Moreover, ctDNA analysis in the clinical setting may guide decision-making 
and potentially facilitate personalized cancer care. It is able to provide 
information on the presence of cancer and its genetic composition and is 
correlated with clinical parameters such as stage, disease burden, 
recurrence, and response to treatment. In BC, recent studies have 
indicated the versatile role of ctDNA analysis in determining the genomic 
profile of tumors, to sensitively and specifically identify preclinical 
metastases and predict a relapse ahead of its diagnosis, and to assess 
resistance to targeted therapy or to uncover tumor heterogeneity21. In 
another study, the molecular profile in serial ctDNA samples from BC 
patients was monitored and it was demonstrated that ctDNA sequencing 
provides dynamic information on somatic variants with pathogenic effects 
in tumors. The molecular analysis revealed that patients with lower-grade 
and luminal A BC subtype and patient with low-grade luminal B subtype 
had somatic pathogenic variants detected only in their ctDNA prior to 
surgery. This correlates with a generally better prognosis of the luminal A 
subtype compared with other BC subtypes. Detection of somatic 
pathogenic variants in ctDNA only after surgery was associated with 
patients of unknown HER2 status and luminal B, and unknown luminal 
type; but these patients had higher-grade (G2 or G3) cancer. While patients 
with luminal B, HER2+ and grade 3 had somatic pathogenic variants 
detected in ctDNA only after chemotherapy, restricted patient numbers, 
lack of characterization and impossibility of analyzing certain samples 
prevented significant conclusions from these results22. 
In a recent study a PIK3CA and TP53 mutations in matched ctDNA samples 
before biopsy and tumor biopsy samples in patients with early BC were 
analyzed. Concordance between ctDNA mutations and biopsy mutations 
was observed in only 8/29 (27.6%) patients. All patients with concordant 
mutations had higher-grade disease. Somatic PIK3CA mutations were 
identified in 19/29 (65.5%) patients. TP53 mutations were identified in 
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6/29 (20.7%), and 4 patients (13.8) had both PIK3CA and TP53 mutations. 
Therefore, these analyses could identify tumor heterogeneity, improve the 
diagnosis of early BC patients, and provide significant information23. Similar 
studies have been performed in ER+ and TNBC and showed ctDNA genomic 
changes in patients with ER+ metastatic BC (mBC) by hybrid capture-based 
genomic profiling. The time-matched ctDNA and tissue samples from 14 
patients and 89% of mutations in tissues were also present in the in ctDNA, 
but mutations in ESR1, TP53 and PIK3CA were detected only the in ctDNA 
samples has been analyzed24. This detection of extra mutations in ctDNA 
could support liquid biopsy use in detecting heterogenous metastatic sites 
in ER+ mBC. Moreover, a retrospective study using cfDNA to determine 
somatic copy-number variations in primary and metastatic tumors and 
cfDNA tumor fractions were conducted in patients with TNBC. The work 
highlighted that cfDNA tumor fractions ≥10% were significantly associated 
with worse survival. These results add to the mounting evidence 
supporting the utility of ctDNA as complementary analysis to tissue biopsy 
for thorough molecular profiling of tumor variants25. Finally, it was 
demonstrated that next generation ctDNA sequencing is useful for 
monitoring the changes in somatic variants with pathogenic effects in 
patients with BC, and this analysis can supplement the results of tumor 
tissue biopsy. However, in BC, ctDNA analysis has a low sensitivity of 
detection (<40%), in part due to the low frequency of common mutations 
in BC. Nevertheless, its detection has been already proved to great value in 
clinical settings, where liquid biopsies are now starting to be included in 
the validated tests panel used to detect mutations for target therapies, 
such as the use of Alpelisib for the treatment of patients with hormone 
receptor-positive, HER2-, and PIK3CA-mutated advanced or metastatic BC 
progressed after previous endocrine therapy as monotherapy26.  
 
1.4      Ex  
Ex are 40-100nm diameter membrane vesicles of endocytic origin, which 
are secreted by various kinds of cells and contain a broad repertoire of 
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molecules, including nucleic acids (ex., DNA, mRNA, miRNA, long and short 
noncoding RNA), proteins (ex., cytoskeletal proteins, transmembrane 
proteins, and heat shock proteins), and enzymes (GAPDH, ATPase, pgk1). 
Generally, contents of Ex can reflect the nature and status of the cells of 
origin. The upgrading of specific proteins and nucleic acids implies a degree 
of specific cellular sorting into Ex.  
On the other end of spectrum, Ex have the ability of modulating cellular 
activities in recipient cells by transferring genetic information27. Ex has 
endocytic origin, which shaped from inward budding of membrane of 
multi-vesicular bodies (MVB) and released from the cell into the 
extracellular environment with the plasma membrane. There are a large 
number of mobile membrane-limited vesicles called extracellular vesicles 
(EVs) in the extracellular environment, which can be further 
subcategorized based on their size, biogenesis and release mechanism, and 
content into Ex, micro-vesicles (MVs), and apoptotic bodies. Ex and MVs 
have a distinct biogenesis, while the most dramatic difference between Ex 
and MVs is how they are formed: Ex are formed from inward budding of an 
endosome resulting in a multivesicular body (MVB), with the plasma 
membrane, which is secreted by succeeding fusion of the MVB. On the 
other hand, MVs are released directly by budding from the cellular plasma 
membrane 28. 
Up today, the biomarker research has been mostly focused on Ex analysis, 
since Ex analysis provides several advantages as liquid biopsy and their 
application as a potential complement to personalized medicine in some 
common malignant tumors. Ex exist in almost all body fluids and possess 
high stability encapsulated by lipid bilayers that can reduce the cost of 
sample short-term storage and the difficulty of transportation, which 
greatly enhances the clinical applicability; Ex are secreted by living cells and 
contain biological information from the parental cells and be more 
representative than cell-free DNA (cfDNA), which is secreted during 
necrosis or apoptosis; Ex identification is easier compared to other 
circulating biomarker, such CTCs,  because they express specific proteins 
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which can be used as markers to effectively distinguish them from other 
vesicles; finally, Ex can present specific surface proteins from parental cells 
and even target cells, which can realize the isolation of origin-specific Ex 
and predict organ-specific. 
However, there are still some barriers between basic research and real 
clinical practice: a standardization of the classification and extraction 
method for different body liquids is needed and the identification of 
specific subtypes of EVs is necessary, as different vesicles may exert various 
biological effects. Therefore, the standardization of protocols and 
identification methods are required when attempting to widely use Ex in 
clinical testing; although many molecules carried by Ex have been 
documented to serve as potential biomarkers, little of them are qualified 
for application; last but not the least, as potential therapeutic cargo, the 
biological safety, and targeted efficacy29 have to be verified. 
Recently, research on the role of Ex involved tumorigenesis and cancer 
progression has grown exponentially, including immune suppression, 
angiogenesis, cell migration and invasion. As Ex are capable of transferring 
specific proteins and nucleic acids to recipient cells in the tumor 
microenvironment or at specific distant sites, Ex could be the tool by which 
cancer cells can transfer malignant phenotype to normal cells and establish 
a fertile local and distant microenvironment to help cancer cell growth. 
Increasingly, Ex are studied for their potential roles as both indicators of BC 
and a prospective new treatment approach, explained by the fact that they 
can play important roles in different stages of development in BC30.  
Ex also exert a feedback mechanism regulating the release of Ex from 
normal mammary, it means that those who are released from BC cells and 
normal human mammary epithelial cells are regulated by Ex derived from 
their own cells.  Through horizontal transfer of genetic information 
between BC cells, Ex are supposed to exhibit pleiotropic biological 
functions, including stimulating tumor angiogenesis, reorganizing the 
stroma to establish the tumor microenvironment, as well as promoting 
tumor growth and drug resistance. In details, during initial malignant 
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transformation, Ex generated by BC cells contain a variety of proteins and 
RNA species can be transfected between cancer cells as well as cancer and 
normal cells, conferring a transformed-like phenotype to normal mammary 
epithelial cells.  
Although the exact underlying mechanisms remain to be elucidated, Ex 
could alter the transcriptomes of target cells and contribute to oncogenic 
transformation and tumor formation. For example, Ex secreted by a 
specific BC cell line were capable of transforming normal human mammary 
epithelial cells into cancer cells. At the same time, in BC cells hypoxia 
condition is regarded as a major trigger for Ex secretion. This is a transient 
phenomenon presents at microscopic sites within tumor 
microenvironment, which is linked to angiogenesis, tumor aggressiveness, 
treatment resistance and poor outcomes. With a unique ability, cancer 
cells can survive and grow under hypoxic environments. In these 
conditions, the effects of Ex on tumor angiogenesis and growth are even 
more noticeable: hypoxia-induced release of Ex from cancer cells may lead 
to neoplastic transformation, malignant cell growth and invasion31. 
Since BC therapy has received many restrictions due to explanation of 
mechanisms responsible for drug resistance, a reliable indicator to predict 
the therapeutic effect, is essential to achieve more effective and 
individualized chemotherapeutic treatment of BC patients. Currently, some 
studies have shown that BC Ex-mediated transfer of genetic information 
can induce therapy resistance and promote tumor progression, such as 
extruding hydrophilic drugs from cancer cells. Moreover, it is also implied 
the roles of Ex in BC chemotherapy or radiotherapy resistance and cancer 
immunotherapy. Radiotherapy is a significant treatment method in BC. 
Generally, oxygen is indispensable for radiation cytotoxic to cause DNA 
damage, thus, BC can be more resistant to radiation therapy under hypoxic 
microenvironment, and hypoxia could lead to the increased production of 
Ex. Besides, Ex transferred from stromal to BC cells stimulates antiviral 
signaling and derived radiation resistance in primary tumor: drug-resistant 
BC cells may spread resistance capacity and alter chemo-susceptibility in 
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recipient sensitive cells via intercellular transfer of Ex. Finally, tumor Ex 
carrying antigens that are targets for anti-tumor antibodies, therefore 
competitively inhibit the drug activity and contribute to immunotherapy 
failure32.  
Overall, Ex have been proven to be important regulators in health and 
disease, especially in tumor biology. It is well known that tumor derived Ex 
enclosing tumor-specific antigens and nucleic acids can be assessed non-
invasive as potential diagnostic and predictive biomarker.  
Besides, Ex could potentially be used to identify patients who are likely to 
develop metastatic disease, and the process of Ex production could yield 
new targets for cancer therapy. With the development of novel therapeutic 
strategies targeting or utilizing Ex, it will lead to more effective prevention 
and intervention strategies in BC therapy. However, it is critical to note 
that crucial contents of Ex are still not fully elucidated, and as a 



















































2. THESIS PURPOSE 
 
The purpose of this thesis is to verify the technical feasibility and possible 
clinical utility of liquid biopsy in BC clinical contest at Ospedale Policlinico 
San Martino.  
The work has been carried out in two translational protocols: mainly, a 
translational study aimed to detect and characterize CTCs, together with 
ctDNA, (CITUCEL trial); part of the work was conducted within a study 
designed to evaluate which circulating biomaterial obtained by liquid 




2.1      CITUCEL 
This project presents the preliminary results of the translational protocol 
CITUCEL “CIrculating TUmor CELls (CTCs) and circulating tumor DNA 
(ctDNA) in BC patients: a prospective study”.  
This is a no profit study and takes the advantage of a close collaboration 
between different groups at Ospedale Policlinico San Martino: the 
Molecular Diagnostic Unit (Dr. Zupo/Dr Dono/Dr. De Luca) and the Clinic of 
Internal Medicine (Prof. Ballestrero/Dr Anna Garuti). 
The study was approved on February 4th, 2016 by the Local Ethic 
Committee and made operative on May 4th, 2016 with administrative 
resolution no. 0519. 
In a period between February 2017 and January 2020, 60 patients with 
invasive BC were enrolled at the SDD Breast Unit of the Ospedale 
Policlinico San Martino. 
 
Inclusion Criteria: 
- Patients with histological diagnosis of invasive carcinoma undergoing 
neoadjuvant chemotherapy (stage IIB, III tumors). 
- Patients with histological diagnosis of invasive early stage BC at high risk of 
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relapse (stage IIB tumor) undergoing adjuvant chemotherapy. 
- Patients with histological diagnosis of metastatic BC candidates for a first 
line of treatment. 
- Patients with histological diagnosis of metastatic BC progressing to first-
line endocrine therapy. 
- Patients must have signed informed consent. 
 
Exclusion criteria: 
- Patients with histological diagnosis of invasive BC undergoing neoadjuvant 
therapy for stage IIA (T1N1 or T2N0) neoplasia. 
- Patients with histological diagnosis of invasive early-stage BC with low or 
intermediate risk of relapse (patients not candidates for adjuvant therapy, 
patients’ candidates for adjuvant therapy with luminal A subtype at any 
stage and those with TNBC or luminal B or HER2+ with N<4). 
- Patients with a histological diagnosis of metastatic BC progressing to >1 
line of chemotherapy for advanced disease. 
- Patients with a histological diagnosis of metastatic BC progressing to ≥2 
lines of endocrine therapy for advanced disease. 
 
 
2.2      BaReLiB 
TNBC is defined by the absence of ER, PR and HER2 expression. TNBC are 
generally more aggressive tumors: patients have a relatively poorer 
outcome compared with those with other BC subtypes and have a higher 
risk of both local and distant recurrence.  
Nearly, only around 30-40% of TNBC patients achieved a pathological 
complete response (pCR) after neo-adjuvant chemotherapy. Currently 
adopted classification considers 4 TNBC subtypes33.   
Similarly, the prognosis of patients with HER2+/HR- BC, a very aggressive 
subtype, is poorer if they did not achieve pCR after neo-adjuvant therapy. 
These evidences suggest a marked heterogeneity and consequent 
differential responsiveness to chemotherapy.  
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An important issue in BC field is represented by tumor heterogeneity, 
defined as heterogeneity within the tumor or between the primary tumor 
and metastatic sites within a same patient. Besides the inter-tumor 
heterogeneity, the picture is further complicated in the intra-tumor clonal 
heterogeneity, which may have profound clinical implication.  
This study aims to systematically evaluate the reliability of ctDNA, CTCs and 
Ex (CBM) in featuring the heterogeneity of TNBC or HER2+/HR- BC 
xenotransplanted mice using an unprecedentedly powerful technique 
based on genetic barcoding and NGS. 
The sensibility and specificity of the individual CBM in representing tumor 
heterogeneity has not been evaluated yet: to determinate which of those 
could be the more representative biomarker for the study and treatment 
of TNBC and HER2+/HR- is therefore of crucial importance.  
A systematic analysis of these aspects implies the ability to recognize a 
large number of genomic assets simultaneously; therefore, it has been so 
far impractical even in animal models.  
The recent development of NGS opened the opportunity to analyze 
unparalleled amount of genetic materials. This provides a tool to detect a 
huge number of artificial genetic labels (barcodes) that can be inserted in 
tumor cells prior xenotransplantation, allowing to systematically monitor 
tumor clones and CBM released by them.  
This analysis will allow to establish how many different clones compose the 
tumor masses and how large they are. In particular, this project has the 
propose to exploit genetic barcoding and NGS to directly compare the 
performance of the different CBM analysis in a mouse model of primary TN 
or HER2+/HR- BC cells xenografts.  
This protocol brings together different expertise within the Institute: a 
deep experience in clinical practice of BC (Prof. Lucia Del Mastro) and 
patient CTCs isolation (Dr. Barbara Cardinali).  
A long lasting experience in primary culture enriched in TIC and the derived 
mouse model of cancer (Dr. Antonio Daga); a skilled training in Ex isolation 
and analysis (Dr. Roberta Tasso); a strong background in molecular and 
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cancer biology with a special feeling for computational biomolecular 
analysis and NGS applied to different tissue types (Prof. Paolo Malatesta; 




The ubiquitin-proteasome signalling pathway plays a critical role in several 
processes regulating cellular homeostasis and survival. It represents the 
main non-lysosomal route for degradation of misfolded, oxidized, damaged 
proteins. Non-lysosomal mechanisms are responsible for the highly 
selective turnover of intracellular proteins that occurs under basal 
metabolic conditions, but also for some aspects of degradation of 
intracellular proteins under stress.  
An important non-lysosomal proteolytic pathway is the ubiquitin system in 
which proteins are degraded by a 26s protease complex following 
conjugation by multiple molecules of ubiquitin. The catalytic core of the 
complex is a 20s protease complex also known as the proteasome34. 
MLN9708 (Ixazomib) is a second-generation small-molecule proteasome 
inhibitor approved for the treatment of multiple myeloma (MM) with a 
shorter proteasome dissociation half-life compared to first-in-class 
bortezomib, as well as improved pharmacokinetic, pharmacodynamic and 
antitumor activity35.  
Furthermore, upon exposure to aqueous solutions or plasma, MLN9708 
rapidly hydrolyses to its biologically active form MLN2238.  
Ixazomib is active in some of the major apoptotic signalling pathways. In 
fact, it induces cleavage of caspase-3, an upstream activator of PARP-1 and 
decreases cyclin D1 and its target protein Cdk6. 
In MM cells, apoptosis induced by MLN2238 has been shown to be 
caspase-dependent, since this compound is able to activate both caspase-9 
(intrinsic) and caspase-8 (extrinsic) apoptotic pathways through the 
involvement of other signalling pathways, such as p53-p21, p53, NOXA, 
PUMA, and ER stress36. 
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A previous preclinical study has shown that in BC cell lines this drug could 
lead to specific tumor cell death through apoptosis activation caspase-3 
and PARP-mediated mechanism37. 
It has been demonstrated the activation of pleiotropic cell death signalling 
cascades in response to proteasome inhibition. This is likely due to the fact 
that the majority of cellular proteins undergo degradation through 
proteasome, and blockade of proteasome negatively affects this normal 
cellular process resulting in accumulation of unwanted proteins and 
subsequent activation of multiple cell death signalling38. 
Bendamustine is a drug used for the therapeutic treatment of MM. It is a 
bifunctional alkylating agent that combines the alkylating properties of 2 
chloroethylamine and the antimetabolite properties of a benzimidazole 
ring. Bendamustine induces cell death by the activation of apoptosis and 
the DNA damage response, acting as an alkylating agent that induces inter-
strand DNA crosslinking and subsequent strand breaks39.  
Until now, the potential therapeutic effect of Ixazomib and/or 
Bendamustine on BC remains unknown.  
A pilot in vitro study was developed starting from this data and clinic 
evidences: a 68-year-old patient who experienced MM and BC was treated 
at Ospedale Policlinico San Martino with Ixazomib and Bendamustine.  
 
In details: 
Clinical case (S. A. 68 years woman) 
February 2017: diagnosis of MM  
21/2/17: staging PET scan revealed a right breast lesion confirmed by 
mammography and breast ultrasound (9mm right QSI) 
6/3/17: right breast biopsy positive for ductal invasive carcinoma ER 99%, 
PgR 99%, Ki67 13% HER2 1+; clinical TNM: cT1N0 
2/3/17: start induction therapy: MM in UNITO-EMN10 Trial with MLN9708 
4 mg orally on days 1,8,15 or desamethasone 40mg orally on days 
1,8,15,22 or Bendamustine 75 mq/mq iv on days 1,8 
6/7/17: Mammography and breast ultrasound negative for breast lesions. 
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To treat the patients, priority was given to the treatment for MM. Surgery 
for BC was delayed and the patient started dexamethasone, Ixazomib and 
Bendamustine, the MM induction therapy.  
Intriguingly, a complete response of BC was observed by mammography 
and PET scan. It is therefore possible to hypothesize that the clinical 
response for BC was induced by the treatment with Ixazomib and/or 
Bendamustine.  
This project proposes to determine if Ixazomib, Bendamustine or their 
combination could be effective in the cure of BC using in vitro assays on 
different BC cell lines and put in evidence if this effect could be a BC 
subtype specific.  
The results of this study could lead to the development of new diagnostic 






Our aims are: 
1) To perform a correlation between: 
- the presence of CTCs, ctDNA and the rate of pathological complete 
response (pCR) in BC patients treated with neoadjuvant therapy.  
- the presence CTCs, ctDNA and disease-free survival/overall survival in 
(neo)adjuvant therapies.  
- the presence CTCs, ctDNA and the progression-free survival/overall 
survival in first line therapy.  
2) To assess the mutational profiles of primary tumour, CTCs and ctDNA at 
different time-points for a comparative analysis of these profiles in the 
adjuvant, neo-adjuvant and metastatic settings.  
 
A total of 60 patients were planned to be enrolled in three years. Eligible 
patients undergo peripheral blood sampling according to specific timings:  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- For patients undergoing neo-adjuvant CT: at baseline and at the end of 
neoadjuvant therapy, before surgery 
- For patients undergoing adjuvant CT: before and after the end of 
adjuvant chemotherapy. 
- For metastatic BC: at the time of initiation and at progression to first-
line therapy 
 
For all the patient’s data were obtained on: tumor characteristics, 




The study aims to: 
- Evaluate the reliability of various CBM in featuring the 
heterogeneity of TNBC. 
- Determine the representativeness of tumor mass in the different 
clones recovered from the different circulating biological 
biomaterials (CTC, cDNA and Ex). 
- Evaluate the proportion between cell number and single clones in 
the different circulating biological components. 
- Evaluate of the lower limit of detection of single clones in the 
different CBM. 




3.3         Ixazomib  
   In vitro experiments have been conducted with the aim to: 
- Evaluate of the activity of Ixazomib, Bendamustine or their 
combination on BC cell lines.  
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- Characterize the biological mechanism involved in the possible 
































4. MATERIALS AND METHODS 
 
4.1      CITUCEL 
4.1.1. Sample collection and treatment 
Enrolled patients underwent a peripheral blood sampling through venous 
access. Five samples of 6mL each were collected in tubes containing 
Ethylenediaminetetraacetic acid (EDTA) as anticoagulant, following specific 
timings. In particular, for patients treated with neoadjuvant chemotherapy, 
samples were taken before and at the end of neoadjuvant chemotherapy 
before surgery; for patients undergoing adjuvant chemotherapy, samples 
were taken before and after the end of the chemotherapy treatment; 
finally, for metastatic patients, the samples were collected before the 
beginning of treatment and eventually at the time of disease progression. 
Blood samples for CTCs and ctDNA analysis were collected simultaneously 
and the material was processed in a short time, when possible within an 
hour from blood withdrawn. The correct timing was ensured thanks to the 
close collaboration between the research nurse and researchers at the 
Breast Unit. 
• CTCs: the extraction and recovery of CTCs is conventionally carried out 
from 7.5mL of whole blood. In this study, blood sample in EDTA was 
stored at +4°C from the time of collection until the first step of the 
enrichment procedure, the start of which was standardized between 
half an hour and an hour from blood collection. 
• ctDNA: ctDNA extraction is carried out from plasma. Experimentally, 
plasma was obtained from approximately 12mL of whole blood. Due 
to the low stability of cfDNA, plasma preparation, based on two 
consecutive centrifugations at 4°C for 10 min, was performed within 
two hours of collection. The blood sample was centrifuged a first time 
at 1600xg in order to separate the plasma from the cellular 
component; a second centrifugation at 1600xg, on the plasma sample 
collected in a new conical tube, was carried out to eliminate any 
residual cellular trace from the isolated plasma. Recovered plasma, 
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about 4-5mL for each patient, was stored at -80°C until the ctDNA 
extraction. 
 
4.1.2. Experimental workflow 
The analyses of CTCs and ctDNA were carried out in parallel on samples 
collected simultaneously and processed according to the experimental 
workflow (shown in Fig. 1), based on the close collaboration between the 
SSD Breast Unit (patient enrollment, recovery and characterization of 
CTCs), SC Clinic of Internal Medicine (patient enrollment and ctDNA 
analysis) and UOS Molecular Diagnostic (mutational analysis of CTCs and 
tissue). 
 
Fig. 1 CITUCEL protocol experimental workflow 
 
4.1.3. CTC enrichment and recovery 
CTCs are traditionally defined as larger cells with irregular shape or 
subcellular morphology positive for citokeratines and EpCAM, which 
demonstrate epithelial origin, and negative for CD45, indicating the cell is 
not of hematopoietic origin. However, EpCAM negative CTCs exist, because 
of the epithelial-to mesenchymal-transition: thus, these CTCs may be 
missed by currently available assays based on EpCAM positivity. To 
overcome this limitation, in this study, CTCs have immunomagnetically 
negative selected from peripheral blood by depletion white blood cells of 
(WBC) and red blood cells (RBC) using a methodology adapted form Bulfoni 
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et al. Breast Cancer Research, 2016. Briefly after RBC lysis, CTC were 
immunonegative enriched on magnetic LD columns (Miltenyi Biotec) by 
depletion of normal leukocytes and residual RBCs with an 
immunomagnetic micro-beads cocktails targeting CD45 (antigen expressed 
on all cells of hematopoietic origin except erythrocytes and platelets) and 
Glycophorin A (expressed on mature erythrocytes and their precursor). 
CTCs were collected in the unbound fraction, concentrated, stained for 
nuclei (with HOECHST 33342) and for EpCAM for epithelial origin, CD44 for 
mesenchymal and for the pan-leukocyte (CD45) markers antigens. Then 
CTCs have been fixed, using Inside Stain Kit (Miltenyi Biotec), that is able to 
achieve mild fixation and permeabilization of cells and leaves their 
morphological characteristics intact. Enriched CTCs were further selected 
with a new technology, the DEPArrayTM System. DEPArrayTM is the only 
system available on the market capable of visualizing, moving and 
retrieving small cell populations down to single cells through the use of di-
electrophoretic forces on a software-controlled semiconductor chip. The 
heterogeneous cell populations loaded on the device can be selected 
identifying target cells through the use of different phenotypic markers 
detected by fluorescence and isolate them as individual cells by use of di-
electrophoretic manipulation that allows their movement within the chip.  
 












    Fig. 2 Photograph of the 
DEPArrayTM Instrument at 
Policlinico San Martino 
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Finally, CTCs selection, based on morphological and phenotypical analysis is 
performed in image-based post-recovery analysis: this step is fundamental 
to identify CTCs, to choose the cells of interest, assess their phenotype, and 
identify statistically significant marks.  
Before analyzing patient’s samples, sensitivity and specificity of the 
enrichment method have been verified by spiking experiments using BC 
cell lines: MDA-MB-231 and MCF-7.  
In particular, whole blood samples have been spiked with different kind 
and number of tumor cells, in order to verify the power of the enrichment 
and detection on cell with different phenotypes.  
The rate of recovery and purify of the fractions have been obtained from 
the comparison of the number of spiked tumor cells with the number of 
recovered tumor cells after the enrichment procedure. The specificity of 
the method has been assessed comparing the expression of the selected 
markers on blood cells of healthy donors by FACS analysis. 
 
4.1.4. Isolation, extraction and quantification of cell-free DNA (cfDNA) 
The analysis of circulating free DNA (cfDNA) samples from cancer patients 
is able to provide detailed prognostic and predictive information, data on 
the response and resistance to treatment and on the evolution of the 
disease. 
In this trial it was chosen to use a multigenic approach in NGS with the use 
of a single panel capable of investigating multiple variants simultaneously, 
rather than the Digital PCR Technique, which is often used for these 
analyses, since it would allow to detect a specific mutation at a time and 
requires a significant amount of DNA and to know in advance the alteration 
to be searched for. 
CtDNA extraction was carried out with the Maxwell® RSC LV ccfDNA Kit 
(Promega Corporation) on the Maxwell semi-automatic extraction system 
as per commercial protocol, starting from 3/5 mL of plasma, on average 
4mL. The extracted DNA was quantified in two ways: 
1) using the QubitTM dsDNA HS Assay Kit (InvitrogenTM) designed to 
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be used on the QubitTM 2.0 Fluorometer (InvitrogenTM). 
2) through High Sensitivity D1000 ScreenTape system designed for the 
Agilent TapeStation 2200 platform and capable of quantifying DNA 
molecules between 35 and 1000bp. 
 
4.1.5. Mutational analysis 
Mutational analysis was performed using NGS approach that has been 
remarkably improved in the last years, providing numerous advantages in 
recent generations of instrument that are faster, cheaper devices 
producing better-quality data, requiring less genetic material and less 
reagents compared with previous ones.  
In the CITUCEL protocol, the Ion Torrent platform was used.  
In particular the analyses were carried out on an Ion Torrent S5, 
intermediate between the second and third generation, that is a unique 
instrument because it uses semiconductors (Ion Chips) as structural 
element of the supports in which the sample is dispensed for sequencing 
and uses a detection system not based on easy luminescent reactions to 
decay, but on potential variations. 
Briefly, this analysis involves four different phases: 
 
1) Building the library 
2) Preparation of the template / library amplification 
3) Sequencing 
4) Data analysis 
 
Fig. 3 Mutational analysis phases in NGS 
 39 
 
The mutational analysis was performed in NGS using for both ctDNA and 
CTCs analyses the OncomineTM Breast v2 cfDNA Assays (OBcfRAv2-
ThermoFisher Scientific) panel designed for the detection of somatic 
mutations in plasma with a limit of detection (LOD) even below 0.1% in 
genes considered to be of clinical utility in BC.  
The panel covers more than 150 hotspot genomic locations distributed 
across 10 genes: AKT1, EGFR, ERBB2, ERBB3, ESR1, FBXW7, KRAS, PIK3CA, 
SF3B1 and TP53; includes analysis of copy number variations (CNVs) 
CCND1, ERBB2, FGFR1. 
 
• CTCs 
In this regard, a method designed for the mutational analysis of CTCs 
through NGS has been optimized and developed in house and recently 
published40.  
The validated methodology is performed without the pre-amplification 
step, namely without applying the so-called whole genome amplification 
(WGA) which allows to obtain sufficient DNA molecules starting from small 
samples such as those containing a few isolated CTCs, with the aim of 
eliminating errors usually introduced with such amplification.  
The NGS protocol, originally created for the study of free circulating cfDNA, 
has been adapted for the molecular characterization of CTCs; it is based on 
the very sensitive technology of "molecular tagging", which allows to 
intercept even a single DNA molecule within a sample and recognizes a 
true mutation from a DNA amplification/sequencing error. Detailed 
description in paragraph 5.1.4. 
 
• ctDNA 
As mentioned above, the library size was assessed using the Agilent High 
Sensitivity DNA Kit by Tapestation 2200 instrument, and the library 
concentration was determined with the Fluorometer 2.0 using the 
QubitTM dsDNA HS Assay Kit.  
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Template preparation was conducted on the Ion Chef System (Thermo) and 
sequencing conducted on the Ion 540TM chip with the Ion S5 platform to 
obtain coverage ≥25,000X, as per company specifications. 
 
4.1.6. Tissue analysis 
Mutational analyses of the patients' baseline tumor samples were 
performed in NGS with a dedicated panel based on Ion AmpliSeqTM 
technology. The panel was designed to study the common alterations 
found in BC in order to incorporate also the mutations included in the 
Oncomine Breast V2 panel and includes 291 amplicons distributed in 20 
genes (ie, TP53, PIK3CA, ERBB2, ERBB3, ERBB4, ESR1, MCL1, GATA3, PTEN, 
CCND1, KRAS, AKT1, CDH1, MAP2K4, SF3B1, FBXW7, MAP3K1, PIK3R1, 
EGFR, and FGFR1). 
Genomic DNA was manually extracted from FFPE samples with the 
instrument QIAsymphony (Qiagen, Milan, Italy).  
To improve the extraction yield, the tissue was micro-dissected in order to 
obtain samples with at least 50% of tumor cells.  
The extracted DNA was quantified with the QubitTM 3.0 Fluorimeter and 
used for the automatic construction of libraries on the Ion ChefTM using 
the Ion AmpliSeqTM Kit for Chef DL8 (ThermoFisher Scientific, Carlsbad, 
CA, USA) and the libraries were analyzed on the Ion 520TM Chip.  
Sequencing was performed on the GeneStudioTM S5 Torrent platform. 
The data were analyzed on the Ion Torrent Suite and the annotation of the 
variants was done with the Ion Reporter Software (version 5.10, 
ThermoFisher Scientific, Carlsbad, CA, USA). 
 
4.1.7. Statistical analysis 
In order to analyze the differences in CTCs number and CtDNA 
concentration between the different settings time points, the statistical 
analysis was conducted with classic tests (X2 or Fisher, Mann Whitney, 
Kruskal-Wallis tests), using the Stata SE version 14 software. The 
differences were considered significant if P-value <0.05. 
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4.2       BaReLiB 
The experimental activity carried out in this PhD project has been focused 
on the enrichment and recovery of CTCs.  
In the BaReLiB study (Fig. 4 represents the experimental workflow) all the 
experiments regarding the setting up of culture condition, the xenografting 
of barcoded cells into immunodeficient mice and NGS analysis have been 
done by Molecular Biology Unit at HSM.  
 
4.2.1 Cell line set-up 
MDA-MB-231 cell line (TNBC human cell line) and primary cells derived 
from patients’ resected tumors have been individually transduced by a 
retroviral library that carries a degenerated barcode and the GFP gene and 
then xenotransplanted in immunodeficient mice.  
Following the development of the tumor, CBM and the tumor mass have   
been collected.  
 
Fig. 4 Experimental workflow 
 
4.2.2. Enrolling TNBC patients, setting up the culture conditions for TNBC cells 
Triple negative BC or HR2-/HER2+ Tru-Cut biopsies or post-surgical 
specimens histologically diagnosed according to the WHO classification, 
have been provided by the SSD Breast Unit after patients’ informed 
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consent. Tumor fragments collected immediately after surgical resection 
were mechanically dissociated to obtain single cells. Then cells were grown 
in vitro as mammospheres, using MammoCultTM Medium (StemCell 
Technologies) and low attachment plates, in order to preserve their 
stemness and take rate efficiency, with the cell differentiation that results 
minimized. 
 
4.2.3. Genetic barcoding of TNBC cells with a retroviral library. Xenografting 
barcoded cells into NOD/SCID mice 
With the aim of genetically label single cells of BC cultures with a unique 
barcode, a library of retroviral vectors expressing Luciferase-EGFP (LUC-
GFP) fusion and containing a co-cistronic 22-mer degenerated barcode, 
with a multiplicity higher than 105, were produced in VSVG packaging cells. 
At least 104 cells from each BC culture were infected and expanded in 10 
aliquots.  
Among them, 5 aliquots have been resuspended in 50% Matrigel to 
increase the take rate and xenografted in the interscapular fat pad of 8-12-
week-old female NOD/SCID mice under general anesthesia with the aim to 
obtain at least 3 mice successfully xenografted for each BC patient.  
 
4.2.4. Characterization of xenotrasplantable TNBC samples 
One of the remaining aliquot of each BC sample able to engraft in mice was 
analyzed by NGS, in order to determine the entire set of barcodes actually 
labelling the original culture.  
 
4.2.5. Recovering of liquid biopsies and primary tumors 
At the moment in which the xenotransplanted BC reaches a volume of 1 
cm3, mice were killed, and their blood collected.  
Primary tumors were then be micro-dissected with the help of an 
epifluorescence stereomicroscope, allowing to identify tumor LUC-GFP-
positive cells.  
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- Genomic DNA and ctDNA were extracted respectively from primary 
tumor and from the blood using commercially available kits.  
- The enrichment of CTCs from blood has been performed following 
the procedure optimized in our laboratory, which takes the 
advantage of the use of the DEPArray™ System (more details in 
paragraph 5.2.1).  
- Ex have been isolated from plasma obtained from blood by 
sequential centrifugation, using commercial isolation kits such as 
the ExoQuick Exosome Isolation Reagent (Qiagen), which enables 
efficient Ex isolation from as little as 50µl of plasma. Exosomal total 
RNA and DNA were then extracted using commercially available 
nucleic acid extraction kit as previously reported. 
- Barcodes from the different CBM and from primary tumors have 
been retrieved by PCR (or RT-PCR for RNA derived from Ex) by using 
primers annealing on the barcode flanking regions. Successfully 
amplified material was then processed in NGS. 
 
4.2.6. NGS analysis to identify the barcodes in the primary tumors and in CBM  
Amplicons obtained from CBM obtained from few cultured patients’ 
samples were sequenced by NGS and the list of their barcodes compared 
with that obtained from the primary tumor.  
 
4.3       Ixazomib 
4.3.1. Cell lines and culture conditions 
In this study MDA-MB-231, MCF-7 an SKBR3, representing different BC 
subtypes, were used. All the cells were cultured in DMEM medium with 
10% of heat-inactivated fetal bovine serum FBS, penicillin (100 I.U/mL) and 
streptomycin (100 ng/mL) and 1% of glutamine (Sigma, USA). 
Cells were cultured at 37 °C in a 90% humidified incubator with 5% CO2. 
When the cells were 80% confluent, they were sub-cultured to a fresh 
media. Disaggregation was carried out using a 5 min incubation at 37°C 
with a 0.05% solution of trypsin in phosphate-buffered saline (PBS). 
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4.3.2. Chemosensitivity assay 
To study the effect of Ixazomib and Bendamustine the different cell lines 
cells were seeded at different concentration, based on their grown rate. 
Following overnight adherence, the cells were incubated with the medium 
alone or with different concentration of Ixazomib (100 - 50 - 25 - 10μM) or 
with 10μM of Bendamustine, for 24 and 48 hours. Then, 50μL of MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) solution was 
added to each well and mixed. After 4 hours, the supernatants were 
removed and 200μL DMSO was added to each well to dissolve the 
precipitate. The cells viability was estimated by measuring absorbance at 
555nm using SPECTROstar nano.  
The cell viability percentage was calculated based on the absorbance ratio 
between cell culture treated with Ixazomib/Bendamustine and the 





















5.1       CITUCEL 
5.1.1. Enrolment and clinical-pathological characteristics of patients 
Between February 2017 and January 2020, 60 patients with invasive BC 
treated at the SDD Breast Unit and at Clinic of Internal Medicine of the 
Ospedale Policlinico San Martino were enrolled in CITUCEL trial. Each 
patient, after signing the informed consent, was subjected to a peripheral 
blood sample by venous access following specific timings as per protocol. 
A total of 32 patients were enrolled in the neoadjuvant setting, 22 patients 
in the adjuvant setting and 6 patients in the metastatic setting. 
Table 1 lists the characteristics of patients on neoadjuvant therapy. In this 
setting, almost all the patients presented ductal carcinoma, with positive 
estrogen and progesterone receptors and HER2 negative expression. 
Patients underwent to standard clinical therapy for their histology: the 
response to the treatment was 57.25%. 
Few differences were observed in patients undergoing adjuvant therapy, 
most often suffering from hormone positive ductal carcinoma as reported 
in Table 2. It should be noted that the patients undergoing adjuvant 
therapy had diseases with a higher tumor grade.  











Table 1. Characteristics of patients in neoadjuvant therapy 
 
Neoadjuvant 
NUMBER 32 (100%) 










































































    Table 2. Characteristics of patients in adjuvant therapy 
      Adjuvant 
NUMBER 22 (100%) 
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11 (50%) 
 








































Table 3. Characteristics of metastatic patients  
 
      Metastatic 
NUMBER 6 (100%) 
























5.1.2. CTCs analysis in BC patients: phenotypic/morphological 
characterization and enumeration 
CTCs enumeration was performed on the basis of morphological and 
phenotypic characteristics by two independent investigators.  
This identification required a considerable effort in the analysis and 
evaluation on different samples, as the phenotypic and morphological 
expression of the CTCs isolated from patients was markedly heterogeneous 
when compared with the analysis of tumor cell lines (MDA-MB-231 and 
MCF-7) used in the development and validation of the analysis/recovery 
method carried out in the laboratory.  
The heterogeneity concerned both the expression of the markers and the 
size of the cells, as it could be appreciated in Fig. 5.  
In fact, it can be underlined that most of the patients presented negative 
cells with respect to the two markers used (EpCAM and CD44): this 
characteristic was found above all in the early setting where 60% of 
patients in neoadjuvant and 45% of patients in adjuvant presented EpCAM 
positive cell and only 30% and 13.5% CD44 positive cells, respectively. On 
the contrary in 5 out of 6 of the samples analysed from metastatic patients 
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it was possible to recover EpCAM positive cells; these latter samples 
generally showed much larger CTCs than the CTCs recovered from 
candidate patients to (neo)adjuvant therapy. Moreover, almost in all of the 
patients’ samples it has been possible to detect smaller cells, 
morphologically very similar to WBC, expressing CD44 or negative for all 
the marker used. Similar cells have been already described in the literature 
as “non-conventional CTCs” 40b.  
Their clinical significance is still to be proven and deserve a deeper 















Fig. 5 Examples of CTCs isolated from patients’ samples representing the different phenotypes 
detected in comparison with WBC frankly expressing pan leukocyte marker. A “Non-conventional 
CTC” is also listed, representing a group of cells lacking both epithelial and often mesenchymal 
marker and negative for CD45, definitely smaller than “classical” CTCs. 
 
Considering the entire study cohort, the presence of CTCs was 
demonstrated in 59/60 (98%) patients, with a number of CTCs/patients 
above the standard cut-off, considered to be ≥1 in the (neo) adjuvant 
setting and ≥5 in the metastatic setting.  
Table 4 shows the results of CTCs count in the different clinical groups of 
patients. It is possible to appreciate the difference (P=0.03) in the number 
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of CTCs detected at baseline between the patients treated in the early 
setting and the metastatic one, in which the number of CTCs is appreciably 
higher (Fig. 6). The differences between the number of CTCs of the 
neoadjuvant group versus the metastatic group is significant with P=0.006, 
differences that remain significant between the adjuvant versus metastatic 
group (P=0.04).  
 
Table 4. Enumeration of CTCs in the various settings 
 
 Median CTC (Range) 
 Neo Ad MTS 
Tot 10.5 (6-16) 12.5 (7-21) 24 (19-30) 
Neg 7 (4-14) 10 (5-19) 14 (16-21) 
EpCAM pos 1 (0-3.5) 0.5 (0-2) 8.5 (4-13) 
    CD44 pos 0 (0-1) 0 (0-0) 0.5 (0-1) 
 
Finally, no significant difference was found in the number of cells identified 
at the beginning of therapy between patients treated in the neoadjuvant 
and adjuvant setting (Fig. 7). 
Considering the early settings, the assessment of the change in the number 
of cells isolated by liquid biopsy before and after chemotherapy treatment 
surprisingly did not show a significant difference, with a decrease in the 
number of CTCs for neoadjuvant and adjuvant patients of 50% and 47%, 
respectively. Considering the neoadjuvant setting, the count of CTCs before 
systemic treatment correlated with the pathological complete response 
(Fig. 8): in this case there was a significant correlation (P=0.015) between a 
lower number of CTCs at onset with complete response, suggesting and 
confirming the potential prognostic value of this parameter. It should be 
noted that the most marked difference in the number of CTCs was found in 
the positive EpCAMs cells which seem to better discriminate the different 
treatment settings (P=0.023 Neo vs MTS, P =0.035 Ad vs MTS). 
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No significant correlation was found with the clinical features (dimension, 
















            
































                    
                Fig. 8 Correlation between the number of CTCs and pCR 
 
Regarding the cluster’s formation, differently from the evidences reported 
in the literature, their presence was found in most of the patients, both 
before and after treatment in the early setting and baseline in the 
advanced setting. Detected clusters were constitute by [CTC + WBC], or by 
CTCs only, and were mainly composed by two or three cells; WBC + CTCs 












Fig. 9 Examples of cells clusters showing the heterogeneous compositions (CTCs only or 
CTCs with different number of WBC). Aggregates of small cells, often including WBC, have 
been also found. At the moment is not possible to confirm their origin.  
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In many cases CTCs involved were negative for the marker chosen 
(EpCAM/CD44) in clusters with WBC, while more frequently EpCAM 
positive were found in cluster formed by CTCs only.  
The characterization of these clusters and their correlation with therapy is 
still ongoing, but it is possible to put in evidence a decrease of clusters 
number after treatment in both neo-adjuvant and adjuvant patients.  
However, the characterization of those clusters deserves a deeper analysis, 
and the presence of CTCs should be confirmed by downstream mutational 
data: infact, it is not possible to exclude that their presence could be an 
artifact due to the fixation process used in the enrichment procedure. 
 
5.1.3. CtDNA analysis: quantification 
For all enrolled patients it was also possible to extract cfDNA at the same 
time as the CTCs, using a specific commercial kit. 
Table 5 describes the amount of cfDNA (expressed in pg/μL) determined in 
the samples tested from 44 patients.  
As from CTCs enumeration, it is possible to appreciate the correlation 
between the concentration of ctDNA with the burden of disease (P=0.013 
between the three settings), being significantly higher in the metastatic 
patient’ samples, compared to neoadjuvant (P=0.007) and adjuvants 
patients (P=0.03) (Fig. 10).  
 
Table 5. Amount of cfDNA in the analyzed samples of 44 patients 
 
 Median ctDNA (Range µg/µL) 
 Neo Ad MTS 





Fig. 10 Amount of ctDNA in baseline samples 
 
No significant correlation was found between the presence of ctDNA and 
chemotherapy, in regards of detected amount pre- and post-therapy in 




Fig. 11 A. Correlation between the amount of ctDNA before and after therapy; B. Correlation 
between amount of ctDNA and pCR 
A B 
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5.1.4. New markers cocktail 
As previously described, our results showed that most of the detected cells 
were negative for the markers used and this does not give us the 
opportunity to characterize them uniquely. Therefore, we have started to 
develop a more comprehensive labelling cocktails based on multiple 
markers, both epithelial and mesenchymal, which are not present on white 
blood cells (WBC) and could help in CTCs characterization. Unfortunately, 
due to the COVID-19 emergency, it was not possible conclude the 
development of this methodology, therefore only preliminary results have 
been obtained on cell lines. 
A deep literature review was done to make the best possible choice in 
markers selection, on the base of their properties and involvement in 
tumour development: consequently CK, E-Cadherin, MUC1, N-Cadherin, 
Slug, CD146 and Vimentin, were chosen in addition to EpCAM and CD44, 
already in use. Those markers should be useful to discriminate three types 
of CTCs: epithelial, mesenchymal, and epithelial/mesenchymal hybrids.  
As regard epithelial markers, CK are particularly useful tools in oncology 
diagnostics because they provide valuable and already in use markers for 
epithelial malignancies. Moreover, it is known that E-Cadherin plays a 
crucial role in maintaining the polarity of epithelial cells41. It is reported 
that cadherin switching (a decrease in E-Cadherin with an increase in N-
Cadherin) is a feature of EMT in numerous types of malignant tumor42. 
Furthermore, MUC1 was also added to the cocktails in consideration of the 
fact that in TNBC was found a potential mechanism by which MUC1 
contributes to the metabolic process involved in BC. In particular, MUC1 
was selected because it is able to translocate to the nucleus in association 
with β-catenin, represses E-Cadherin expression, and upregulates 
expression of the EMT inducers Snail, Slug, Vimentin, and Twist43.  
Regarding mesenchymal markers, N-Cadherin is associated with a 
heightened invasive potential in cancer. A recent study has demonstrated 
that overexpression of N-Cadherin in BC correlates with invasiveness as a 
result of N-Cadherin-mediated interactions between cancer and stromal 
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cells. The phenotype of BC cell lines was found to undergo 
dedifferentiation from epithelial to mesenchymal as a result of N-cadherin 
transfection without a loss of E-Cadherin expression.  
Finally, N-Cadherin, as a marker of ongoing EMT, is not expressed in normal 
epithelial cells, but its expression has been demonstrated in several types 
of carcinomas. Vimentin is another candidate because it is known to 
express aberrantly in epithelial cancers. Vimentin+ cells are associated with 
high grade tumors and increased tumor proliferation. Moreover, Vimentin 
expression is a rather rare finding in invasive BC and is associated with high 
tumour invasiveness and chemoresistance.  
Furthermore, CD146 is important for endothelial cell migration and 
angiogenesis44. CD146 is expressed at abnormally high levels and is 
associated with a reduction of E-Cadherin in TNBC. CD146 silencing in TNBC 
MDA-MB-231 partly reverses its mesenchymal phenotype, implying that 
CD146-induced EMTs partially explain the mesenchymal and malignant 
characteristics of TNBC. In addition, increasing evidences have supported 
the critical role played by tumor angiogenesis in BC progression45.  
Another potentially important marker is SLUG because it is able to regulate 
the expression of genes responsible for the EMT. Expression of SLUG in 
cells suppresses E-Cadherin expression, which subsequently reduces 
intercellular adhesion and increases cell motility properties46.  
Finally, in order to better detect WBC, which do not express CD45 in the 
same way, two different markers (CD14 and CD16), neutrophils and 
macrophages specific, were chosen. The presence of elevated levels of 
CD14+/CD16+ monocytes with tissue macrophage features and the 
association of this subpopulation with disease is shown in various 
pathological conditions, including cancers.  
The functional significance of CD14+/ CD16+ monocytes is still unclear, but 
in certain disease states CD14+/CD16+ monocytes are able to promote 
tumour growth and express the vascular endothelial growth factor 
receptor (VEGFR)47.  
For this purpose, experiments on WBC, collected from a healthy donor 
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whole blood, were performed to verify that these markers did not give 
aspecific results and to confirm the positivity of CD14+/CD16+, the WBC 
extended marker set. Consequently, the same experiments have been 
done on different BC cell lines representative of BC cancer subtypes: MDA-
MB-231, MCF-7 and SKBR3. The markers expression has been analysed 
using FACS and confirmed no expression of the WBC expanded marker set 
(CD14, CD16 plus CD45) on BC cell lines.  
In regards of CTCs expanded optimised marker preliminary results 
(reported in Table 6) showed that SKBR3 cells, a cell line with 
mesenchymal-epithelial characteristic, are positive for EpCAM, CD44, CK, 
MUC1, CD146 and Slug, while are negative for N–Cadherin, E–Cadherin, 
Vimentin, just as was expected. Furthermore MCF-7, epithelial cells, turn 
out to be positive to EpCAM, CK, MUC1, CD146, Slug and often CD44, while 
are negative for E–Cadherin, N-Cadherin, Vimentin. Finally, MDA-MB-231 
cells, with mesenchymal characteristics, are positive for EpCAM, CK, CD44, 
CD146 and Slug, while are negative for N-Cadherin, E–Cadherin, MUC1, 
Vimentin, CD45, CD14 and CD16. 
 
Table 6. Positivity of the different cell lines to new cocktail markers  
 
On these bases, this new improved labelling cocktail will be tested in 
further experiments in the lab on patient samples in parallel with the 
current method, to check if, the latter actually allows to obtain a more 
accurate detection and characterization.  
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5.1.5. Mutational analysis 
CTCs translational research is also related to the necessity of improving 
molecular methods for a more comprehensive and accurate detection of 
occurring molecular alterations. This could provide a useful tool for early 
detection of the disease at diagnosis as well as in monitoring patients’ 
response to therapy and progression and help in subsequent therapeutic 
choices. 
To date, the major efforts for molecular characterization of CTCs have 
focalized in optimizing genetic analysis protocols consisting in a first step of 
whole genome amplification (WGA), which allows to obtain a sufficient 
amount of DNA from few starting copies. This procedure is usually 
downstream combined with sequencing methods as Sanger or NGS and/or 
other molecular assays, such as comparative genomic hybridization 
approaches. Therefore, within the CITUCEL trial our researchers group 
developed and optimized a workflow which completely abolish WGA step 
for CTCs mutational analysis, taking advantage of a molecular tagging 
technology applied to NGS. The experiments about NGS analysis have been 
done at the Molecular Diagnostic Unit of the Institute (Dr. Zupo/Dr 
Dono/Dr. De Luca). First the protocol was tested on MDA-MB-231 and 
MCF-7 cell lines isolated by DEPArrayTM, used as surrogate BC CTCs. In the 
preliminary NGS assessment, MDA-MB-231 lysates of one, three, and five 
cells were added to normal DNA. Then, these DNA mixtures were 
employed to prepare libraries: two hotspots present in the MDA-MB-231 
cell line—the KRAS p.Gly13Asp and TP53 p.Arg280Lys— and one  PIK3CA 
Glu545Lys in MCF-7 - were followed and detected.  
Consequently, cells were used as a unique starting genetic material, in the 
complete absence of normal genomic DNA or WGA, for subsequent library 
preparation. As this strategy can dramatically decrease the input amount 
of DNA, a specific adjustment of the NGS protocol was developed.  
The entire new procedure presented main technical changes consisting of 
the following four items: DNA derived only from sorted cells was used as a 
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starting material for the preparation of libraries; a three-times volume 
reduction of the reaction reagents was applied for the two PCRs. By 
applying the optimized NGS protocol, a total of 47 libraries were prepared 
from nine different cellular pool types. In particular, three pools composed 
of two, four, and five tumor cells only and four combined pools (4:1, 3:2, 
2:3, and 1:4 MDA-MB-231/leukocytes ratios, respectively) were 
investigated for MDA-MB-231 specific mutations, together with two pools 
of leukocytes only as negative controls. For MCF-7 analysis, duplicates 
were considered for all pools, except for pools consisting of two cells only 
and the 1:4 MCF-7/leukocytes combination, respectively, which were 
tested in triplicate.  
In details, 2μL of Lysis Reaction Mix (Ampli1 WGA kit, Silicon Biosystems, 
Bologna, Italy) were used. MDA-MB-231 cell lysates were processed 
together with 5ng of normal genomic DNA from healthy donor blood and 
MDA/normal DNA mixtures were used for library construction with the 
OBcfRAv2 (ThermoFisher Scientific, Carlsbad, CA, USA).  
Manually prepared libraries were quantified by qPCR assay with an Ion 
Library TaqManTM Quantitation kit (ThermoFisher Scientific, Carlsbad, CA, 
USA), diluted to 50–60 pMol and then multiplexed up to 5 samples for 
automated template preparation on an Ion ChefTM System and loaded on 
an Ion 530TM Chip (ThermoFisher Scientific, Carlsbad, CA, USA). 
Sequencing runs were performed on an Ion Torrent GeneStudioTM S5 
(ThermoFisher Scientific, Carlsbad, CA, USA), according to the 
manufacturer’s user manual.  
In order to obtain an optimized molecular tagging NGS workflow, libraries 
were prepared using directly the 3μL cell lysates from isolated cells as a 
source of DNA.  
The entire protocol for library preparation with OBcfRAv2 was modified to 
adjust the amplification of small quantities of DNA input into a small 
reaction volume. All reactions used for library construction were set-up 
with a 1:3 dilution reduced volume. Thermal conditions and number of 
amplification cycles were maintained as the canonical original protocol 
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suggested. Manually prepared libraries were quantified, diluted, and used 
for template preparation. The only relevant modification consisted of 
multiplexing up to 24 amplified libraries on an Ion 520TM Chip (low-
coverage sequencing). Run sequencing was performed on an Ion Torrent 
GeneStudioTM S5, as described above.  
A successful sequencing was realized in 46/47 libraries (97.9%), with a 
12,272–294,265 range of total reads (median value 83,723). KRAS 
p.Gly13Asp and TP53 p.Arg280Lys variants were successfully found in the 
MDA-MB-231 triplicates, as well as PIK3CA Glu545Lys in MCF-7 (except for 
one combination), regardless of the number of tumor cells present in a 
pool. 
The robustness of this adapted NGS protocol was also demonstrated by the 
fact that no other mutations than those expected were found and by the 
absence of any mutations in negative controls. Consequently, this 
workflow offers the possibility to investigate genetic hotspots from 
independent pools of few cells simultaneously.  
On these bases, this protocol was also validated with CTCs recovered from 
patients’ samples collected within the CITUCEL trial. Thirteen pools of 
different numbers of CTCs (range: 2-6 cells) were recovered and used for 
subsequent NGS experiments. Libraries were successfully prepared and 
sequenced from all the 13 CTCs pools, thus showing that even if this 
analysis was limited in number, the optimized molecular tagging NGS 
workflow was robust when applied to “real” CTCs. Quantification of 
libraries revealed a yield range of 11-107pMol, with an optimal 
performance (in terms of total produced reads) ranging from 20,633 to 
294,305 (results reported in Table 7). 
 
5.1.6. Comparative tissue/CTCs/ctDNA mutational analysis 
Then, mutational analysis on circulating biomarkers and related solid 
tumors was performed on 8 patients (6 patients in neoadjuvant therapy, 1 
patient in adjuvant and 1 patient in first line therapy). Table 7 shows the 
results relating to the mutational analysis 
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The CTCs analysis was carried out on 13 cell pools (from 3 to 6 cells); where 
possible, in fact, 2 or 3 pools were analyzed for the same patient: in 
particular, the analysis was conducted on a sample for patients 5, 7, 9 and 
12; two samples for patients 18 and 51 and three samples for patient 10. 
 
Table 7. Mutational comparison between CTCs, ctDNA and corresponding breast tumor tissue 
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Fig. 12 represents Circulating Tumor Cells (CTCs) recovered from BC 
patients on DEPArrayTM and directly analysed with the optimised method. 
 
Fig. 12 Representative CTCs, obtained from BC patients by DEPArrayTM method and actually analyzed in NGS 
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The results show that it was possible to detect mutations for 6 of the 8 
patients analyzed. In particular, an intronic variant in the TP53 gene (c.1100 
+ 30A> T, chr17: 7573897) was determined in the CTCs of patients 5, 12 
and 24, while patient 7 had a synonymous variant in the TP53 gene 
(p.Arg213 =). It should be noted that all CTCs samples from patient 51 were 
characterized by the PIK3CA mutation (p. Hys1047Arg). 
 The comparison between the mutations highlighted in the CTCs and the 
corresponding primary tumor (analyzed with the custom panel described in 
materials and methods) shows agreement in the mutations found in 6 out 
of 8 patients. In details, 6 out of 8 cases (62.5%; patients 5, 7, 9, 12, and 51) 
were completely concordant, while patient 24 showed partial agreement, 
since the tissue analysis showed an additional mutation by TP53 
(p.Arg248Trp). For 2 patients (patients 10 and 18) a complete discrepancy 
was instead determined: no mutation was found in the CTCs while the 
tissue analysis revealed a variant of TP53 pArg248Gln and p.Cys275Leufs. 
This discrepancy may reflect the intrinsic nature of the CTCs, which can 
both have the same mutational profile of the primary tumor but also 
diverge completely. The comparison with the mutations found in the 
ctDNA shows agreement in 5 out of 8 cases. It is interesting to report that 
the mutations found in PIK3CA (p.E542K) identified in the ctDNA of 
patients 5 and 10 were negative in the corresponding CTCs. This last finding 
is also inconsistent with the mutational profile of the tissue. 
Finally, it is possible to point the presence of other mutations in tissues 
that can only be revealed by the larger custom panel compared to the 
Oncomine Breast V2 panel. 
The mutational analyses of the samples obtained from the other patients 





5.2       BaReLiB 
This study is still ongoing, and the final results are expected for the end of 
2022. In this thesis are presented the evidences obtained so far. 
5.2.1 CTCs recovery from mice blood 
In this project, the PhD research activity was focused on the recovery of 
CTCs from mouse blood, that was developed with an approach similar to 
the procedure applied in the CITUCEL trial to enrich CTCs from patients‘ 
samples. CTCs recovery was optimized performing spike–in experiment 
using GFP-modified MDA-MB-231 cells: the methodology is based on 
immunonegative selection of human CTCs using the same e approach 
already described, which takes the advantage of the use of the DEPArray™ 
System. Briefly, this method has been adapted to recover human CTCs 
from blood mouse samples, using specific antibodies cocktails (Mouse Cell 
depletion kit, Miltenyi Biotech) after mice RBC lysis. Immunonegative 
selection was carried out on LS columns and enriched cells (GFP positive) 
were further labelled with HOERSCH, anti-human CD44 and anti-mouse 
CD45, in order to better discriminate human cell from mouse ones.  
 
Fig. 13 Spike-in experiments on MDA-MB-231 cell line 
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Finally, cells were fixed using Inside Stain Kit (Miltenyi Biotec).  
In vitro experiments demonstrated that with this system it is possible to 
recover human cancer cells from mouse peripheral blood. Cells were 
analysed and selected with DEPArrayTM (Fig. 13) and DNA content has been 
successfully amplified by pCR from single or pooled cells, suggesting that 
this method is reliable.  
 
5.2.2. CTCs recovery from xenotransplanted mice blood 
In vivo experiments have been performed injecting the GFP-modified MDA-
MB-231 cells into NOD-SCID mice. Compared to the analysis of spiked-in 
cells in mouse blood, the identification of CTCs from xenografted mouse 
blood has been not so straightforward.  
 
Fig. 14 DEPArrayTM Analysis from xenotransplanted mice blood. Cells were labelled with anti-human 
CD44 and anti-mouse CD45. CTC were identified and selected as CD45- and CD44+ and/or GFP+ 
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Infact, CTC showed a different morphology and structure, as it is possible 
to appreciate in Fig. 12: they did not maintain round shape, assuming often 
ellipsoid contours, and were found in the majority of cases associated in 
cluster with mouse WBC. Moreover, GFP expression was very low 
compared to original modified MDA-MB-231 cells (Fig. 14). Therefore, the 
collection and the consequent isolation was much more difficult and not 
univocal. The DEPArray™ selection was done in order to obtain as much as 
possible CTCs candidates to be downstream NGS analysed, therefore 
collecting pools including cells or cells aggregates not univocally 
characterised as human derived CTCs. 
 
5.2.3. Barcode recovery from cell culture  
After the development of tumor masses, tissue and liquid biopsies were 
collected and analysed using NGS, by Malatesta’s laboratory. Exploiting in-
house developed software, clonal composition of independent tumors has 
been successfully reconstructed showing a good maintenance of clonal 
heterogeneity in the tumor masses (Fig. 15) but this was almost lost in 
bloodstream, where only few barcodes were detected at ctDNA level (Fig. 
16) and CTCs (10-20 tumor cells detected in 100µl of mouse blood).  
 









Fig. 16 Comparison of the 
retrieved barcodes between 
initial cell culture, derived tumor 
and ctDNA 
 
Those evidences may suggest that the ability to migrate in the bloodstream 
is owned only by few clones. However, additional sequencing analysis 
showed that even if the number of clones is limited, they are not 
consistent between the replicated, indicating that circulating clones are not 
present as multiples copies but are few “single” molecules  
The results obtained with modified MDA-MB-231 cell on xenografted 
mouse blood showed that cell lines could not be a good model to mimic 
human BC formation and CBM dissemination, since the tumor formed was 
well represented but the barcodes found in the circulation were very few.  
However, those preliminary experiments with cell lines allowed to set-up 
the different experimental conditions and verify the study workflow. 
 
5.2.4. Barcode recovery from patients 
After the first part conducted using cell lines, the So far, 21 mouse 
xerographs have been obtained from 3 patients (for one patient was 
possible to use primary and tissues obtained at progression to prepare 
primary culture). In 9 of these 21 xerographs, enriched CTCs were analysed 
in with DEPArray™ system, while the other CTCs were only enriched, in 
order to verify whether or not the cells were lost during the entire 
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enrichment/recovery procedure. In these experiments the identification of 
CTCs was even furthermore complicated compared to cell lines obtained 
from xenografted experiments, as they appeared more aggregated to WBC 
clusters. Data showed an average of 21 cells retrieved from the primary 
culture of first patient, 10 from the sample of the same patient but in 
which their cells were obtained from tissue collected at relapse of the 
disease and 11 from the second patient.  
Preliminary comparative results obtained from NGS barcodes analysis 
showed that ctDNA well represents the primary tumor. Infact, in the 
comparison with barcode retrieved from tumor masses and CBM showed 
that barcodes found in ctDNA are well representative, while very few were   
found in CTC pools. Finally, in regards of Ex analysis, the results obtained so 
far have shown less reliability and more experiment will be necessary.  
 
Fig. 17 Comparison between barcodes from tumor masses and from ctDNA 
 
The work is still in progress and more data are needed to confirm the 
obtained results and to determine which of the CBM is the best in 





5.3.      Ixazomib 
Starting from a case of a patient with MM and BC treated at the Breast 
Unit of Ospedale Policlinico San Martino, we have planned an in vitro study 
to assess the possible therapeutic effect of Ixazomib and Bendamustine in 
BC.  
The results of this part of the research activity were deeply delayed due to 
the COVID-19 emergency. Therefore, only very preliminary data are 
presented. 
To assess the antitumor effect of Ixazomib on BC cells, experiments were 
performed in vitro using different cell lines, representative of different BC 
subtypes: MDA-MB-231 (TNBC cell line), MCF-7 (HR+, PR+ and HER2-) and 
SKBR3 (HR-, PR- and HER2+). 
First, it was necessary to set-up of the optimal concentration, for each BC 
cell lines, in order to obtain a confluence of about 60-70%.  
Toxicity experiments were performed using 10 mM stock Ixazomib solution 
in DMSO (single aliquot 0.5mL to be used for experiment stored at -80°C); 
Bendamustine was obtained already diluted at clinical dose (10mM) from 
HMS Antiblastic Unit.  
The effects of Izaxomib and Bendamustine alone were roughly tested on 
the different cell lines.   
Then preliminary experiments were performed using with 3000 cells/well 
96-well plate of MDA-MB-231, 4000 cells/well MCF-7 and 5000 cells/well 
of SKBR3. Cells were treated with 100μM Ixazomib and 10μM 
Bendamustine final concentration for 24 hours and 48 hours after 
overnight seeding. Control experiments were done incubating cells with 
medium alone. Initial tests showed that Ixazomib has high activity on all 
cell lines (MDA-MB-231>MCF-7>SKBR3), probably due to the high initial 
concentration used.  On the contrary Bendamustine showed basically no 
effect on all the cell lines. Therefore, only a few experiments have been 
done with Bendamustine, as even at very high concentrations of this drug 
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we did not obtain valid results; as a consequence, the experimental activity 
was first focused on finding the optimal concentration of Ixazomib alone.  
The best results were obtained seeding into a 96-well plate 10000 
cells/well MCF-7, 9000 cells/well MDA-MB-231 and 10000 cells/well of 
SKBR3 for the treatment of 24 hours and 7500 cells/well MCF-7, 6500 
cells/well MDA-MB-231 and 8000 cells/well of SKR3 for the treatment of 48 
hours.  
Overall, the only few experiments carried out showed that the effect of this 
drug on our BC cell lines is present both on MCF-7 and on SKBR3, while it is 
even much greater on MDA-MB-231. This behaviour is detectable and 
coherent in both 24- and 48-hour treatments. 
 






 Fig. 19 Treatment with Ixazomib at different concentrations for 24-48 hours 
 
However, these results are different from other study in this contest, in 
which the experiments, executed in the same BC cell line, shown that 
Ixazomib was more efficient on MCF-7 at lower concentration48.  
More experiments are therefore needed to confirm the results.  
Once the more efficient and powerful concentration will be determined for 
Ixazomib, combination experiments will be performed for 24 or 48 hours 
on cell lines, with the aim to evaluate which of these is the most sensitive 
cell line to the treatment and to evaluate if an additive or synergic effect of 




In this study the evaluation of CTCs and ctDNA in different disease settings 
were performed using cutting-edge technologies and innovative 
approaches. In particular, the analysis of the CTCs used an independent 
EpCAM enrichment process and the use of DEPArrayTM technology that 
allows resolution down to the single cell level.  
Furthermore, the analyses of CTCs and ctDNA presents a double aspect: 
the quantitative one, which can provide useful prognostic information, and 
the qualitative one, aimed at molecular characterization, which allows the 
determination of predictive response mutations or monitoring of the 
cloning evolution of the neoplasm.  
The results, although still partial, seem encouraging and fit well into the 
current translational research based on liquid biopsy and are in line with 
the most recent literature. In fact, it has been shown that the ctDNA 
detected in plasma samples after neoadjuvant chemotherapy and surgery 
is correlated with a more rapid relapse of the disease in triple negative 
patients.  
On the other hand, CTCs have been frequently identified in both patients 
with early and advanced disease; with this regard there is a direct 
correlation between the quantity and the prognosis of the disease.  
Considering the results obtained in the CITUCEL trial, presence of cells at 
baseline was verified between the various therapeutic settings and 
correlates with the disease burden and becomes significant between 
neoadjuvant/adjuvant and metastatic patients.  
The cells that most seem to differentiate the settings are the EpCAM 
positive which have been determined in greater numbers in metastatic 
patients than other settings in which most of the CTCs detected were 
EpCAM negative. Focusing on the number of cells found in pre- and post-
therapy blood samples, no significant difference was determined between 
the number of cells found, otherwise it is interesting to underline that the 
number of CTCs determined at the baseline in patients treated with 
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neoadjuvant therapy correlates with the response to treatment, suggesting 
that this value may have predictive significance. Greater strength to these 
considerations is offered by the analysis of ctDNA, which is present in much 
higher quantities in the blood of patients in the advanced setting. As for 
the number of CTCs, there was no significant difference in the comparison 
between the amount of pre- and post-adjuvant and neoadjuvant ctDNA 
amount. Furthermore, the baseline ctDNA concentration does not appear 
to correlate with the complete pathological response in the neoadjuvant 
setting, differently to what was found for CTCs. However, it should be 
noted that the data of the CTCs must be validated by the mutational 
analysis as well as the concentration values of the ctDNA may not derive 
exclusively from tumor DNA. 
The mutational analysis, still ongoing, was carried out on 8 patients but 
already offers promising results. In fact, it has been observed that in some 
cases there is complete agreement between the analysis of ctDNA and/or 
CTCs and the corresponding tumor, while in others there is a discrepancy 
between the identified mutations, suggesting that CTCs and ctDNA could 
provide complementary information both on the biology of the tumor and 
on its evolution.  
Once completed, this analysis could provide additional information on the 
mutational profile of patients and will allow us to determine which 
biomarker in circulation could best reflect the histopathology of the tumor 
and its progression. 
In this perspective to ensure that CTCs became an important prognostic 
and predictive marker of tumor, their unambiguous and standardized 
evaluation is necessary. In fact, the reliability of CTCs characterization is 
still a source of conflict in this field; the next step of the CITUCEL project 
will be the optimization of the detection antibodies cocktails and their 
consequently use in CTCs patients’ samples detection.  
Moreover, one additional point is related to the need of improving 
molecular analysis method for a more comprehensive and accurate 
detection of occurring molecular alteration. Our group already developed a 
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new molecular approach to analyse CTCs mutational profile. Until now, the 
results obtained are encouraging for a possible translational application of 
the proposed approach.  
Based on our results, even if very limited, it is evident that CTCs and ctDNA 
could provide different - and maybe complementary - information. 
Therefore, it could be really important to establish which of those could be 
more representative of the tumor type and tumor progression.  
With the hope to establish this open issue, the study BareLiB has been 
designed. The initial data confirmed that the system is able to label clones 
and to retrieve them maintaining their heterogeneity.  
Moreover, our optimized experiments allow to recover human CBM from 
xenotransplanted mice: using tumor induced by TNBC cell line our 
preliminary data support that the circulating tumor derived biological 
material is very limited (data presented at ACCC 2019, Corfu’ – Grecia).  
On the contrary, initial experiment using patients’ derived cells showed 
that ctDNA seems to well represent the heterogeneity of primary tumor, 
but this result was not obtained analysing CTCs or EX.  
Overall, the identification of the most sensitive liquid biopsy method could 
allow the detection of specific biomarkers necessary to address the 
therapeutic choices and to monitor the response to therapy, contributing 
to improve the clinical treatments, the prognosis and the quality of life of 
BC patients. The results of this study could lead to the development of new 
diagnostic approaches specific for this neoplasia. 
Finally, once optimized, the in vitro study on Ixazomib and Bendamustine 
will provide new data useful to obtain preliminary evidences of the efficacy 
of the use of these drugs in BC treatment, with the possibility to change 





The different and multidisciplinary studies conducted in this PhD thesis 
have the purpose of obtaining a reliable biomarker derived from liquid 
biopsy, that allows not only to have an early diagnostic test but also to 
monitor the therapy and associate their presence with prognosis and 
resistance. 
The data obtained within the CITUCEL trial, using molecular analyses and 
innovative platforms such as NGS and DEPArrayTM, have demonstrated the 
feasibility of CTCs and ctDNA analyzes in various clinical settings.  
The analysis of the CTCs showed numerical and phenotypic/morphological 
differences between early and advanced setting and a correlation of the 
basal count with the pCR. The ctDNA analysis supports and confirms this 
difference information between the various settings. Furthermore, 
promising data on the mutational profile of the tissue and the related 
"circuloma" has been obtained.  
Once completed, the study could provide new data to better define the 
mechanisms underlying tumor progression and resistance to therapies. 
On the other hand, the ongoing trial BaReLiB will provide insight regarding 
which CBM will better represent the heterogeneity of BC. So far, the results 
support the fact that ctDNA well reproduce tumor clonal complexity 
suggesting that it could be implemented in clinic for treatment choice and 
monitoring. 
Finally, the results of the pilot study on Ixazomib could provide new insight 
of a potential novel treatment strategy in BC and could be a starting point 
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